Dr. Muyldermans. S

Biography

Serge Muyldermans obtained a PhD at the ‘Vrije Universiteit Brussel’, Brussels, Belgium in 1982. He was a postdoc at this university at the time the functional Heavy-chain only antibodies were discovered in camelids. He developed a streamlined method to identify rapidly the antigen-specific, single-domain antibody fragments derived from the unique Heavy chain antibodies of cameldids, This technology was used to found Ablynx NV in December 2001, a Belgian private biotech company actively developing protein therapeutics based on single variable domains or NanobodiesTM and currently employing 300 people. In 2003, he became professor at the ‘Vrije Universiteit Brussel’ where he is heading the camel-antibody engineering group in the laboratory for Cellular and Molecular Immunology. Apart from using the Nanobodies as a research tool, we are developing some of our Nanobodies for in vivo diagnostics and for therapy. Serge Muyldermans obtained a PhD at the ‘Vrije Universiteit Brussel’, Brussels, Belgium in 1982. He was a postdoc at this university at the time the functional Heavy-chain only antibodies were discovered in camelids. He developed a streamlined method to identify rapidly the antigen-specific, single-domain antibody fragments derived from the unique Heavy chain antibodies of cameldids, This technology was used to found Ablynx NV in December 2001, a Belgian private biotech company actively developing protein therapeutics based on single variable domains or NanobodiesTM and currently employing 300 people. In 2003, he became professor at the ‘Vrije Universiteit Brussel’ where he is heading the camel-antibody engineering group in the laboratory for Cellular and Molecular Immunology. Apart from using the Nanobodies as a research tool, we are developing some of our Nanobodies for in vivo diagnostics and for therapy.

Research Interest

Cellular and Molecular Immunology